The anti-proliferative activty and moldecular mechanisms of action of gut microbial metabolites against human breast adenocarcinoma cell lines
Ontology highlight
ABSTRACT:
INSTRUMENT(S):
ORGANISM(S): Homo Sapiens (human)
SUBMITTER: 
Muhammad Alsherbiny
LAB HEAD: Deep Bhuyan
PROVIDER: PXD040482 | Pride | 2024-01-16
REPOSITORIES: Pride
Dataset's files
| Action | DRS | |||
|---|---|---|---|---|
| 221105_All.csv | Csv | |||
| Kayla.DerivedFromSearch04b2cd0d-4d7c-4290-8ab2-b778bcb38234.mgf | Mgf | |||
| Kayla.mzid.gz | Mzid | |||
| Raw_data.zip | Other |
Items per page: 5 1 - 4 of 4 |
Similar Datasets
Project description:The combination of natural products with standard chemotherapeutic agents offers a promising strategy to enhance the efficacy of standard chemotherapy by reducing their dosage and side effects. The standard chemotherapeutic drug for breast and other cancer types- doxorubicin(DOX), also known as Adriamycin (an anthracycline) has several disadvantages including severe side effects and development of drug resistance. Recently, we reported the broad spectrum pharmacological activity and potential markers of Australian propolis extract (AP-1). In the present study, we explored the synergistic interactions of AP-1 with DOX against MCF-7 cells by implementing different synergy quantitation models. To identify the potential anticancer metabolites in AP-1, biochemometric and metabolomics-driven study was performed. Furthermore, we evaluated the molecular mechanisms involved by analysing the apoptotic profile (using flow cytometry and proteome array of 35 apoptotic proteins) and oxidative status (using reactive oxygen species detection) of the MCF-7 cells upon treatment with the most synergistic combination. The underlying synergistic mechanism against the MCF-7 cells was also studied using label-free quantification proteomics analysis. Five prenylated stilbenes were identified as the most discriminant metabolites in the most active AP-1 fraction, three of them previously isolated from AP-1 with IC50 values in the range 0.68-2.7 µM against the MCF-7 cells. Strong synergy was observed when AP-1 was combined with DOX in the ratio of 100:0.29 (w/w) as validated by different synergy quantitation models including combination index (CI), HSA, ZIP, LOEWE, and BLISS. AP-1 significantly enhanced the inhibitory effect of DOX (p < 0.05) against the MCF-7 cell proliferation in a dose-dependent manner with significant reduction of ROS production (p < 0.05; compared to DOX alone). AP-1 also enhanced the apoptotic effect of DOX significantly after 24 h of treatment with a shift of DOX-induced necrosis to apoptosis. Significant upregulation of catalase, HTRA2/Omi, FADD together with TRAIL-mediated apoptosis, DR5 and DR4 (p < 0.05) was observed which contributed to the anti-proliferative activity of AP-1 against the MCF-7 cells. The enhancement of pro-apoptotic p27, PON2 and catalase with reduction of anti-apoptotic XIAP, HSP60 and HIF-1α may be associated with the improved apoptosis in the MCF-7 cells observed in the Annexin V-7AAD flow cytometry analysis of the synergistic combination compared to the mono treatments. Furthermore, a significant increase of antioxidant proteins including catalase and PON2 was observed upon treatment with the synergistic combination which may be associated with the parallel enhancement of apoptosis. Shotgun proteomics in the synergistic combination-treated cells identified 21 significantly dysregulated proteins involving the TP53/ATM-regulated non-homologous end-joining pathway and double-strand breaks repairs, recruiting the overexpressed BRCA1 and curtailed RIF1 encoded proteins. The overexpression of UPF2 was noticed after the treatment with the synergistic combination which could assist to overcome doxorubicin resistance-associated long non-coding RNA and decline the metastasis of the MCF-7 cells. In summary, we propose a promising AP-1 and DOX synergistic combination against the MCF-7 cells and highlighted the possible synergistic mechanisms of action together with the key prenylated metabolites of AP-1. Further in vivo and clinical studies are warranted on this synergistic combination.
2021-07-26 | PXD026331 | Pride
Project description:Milk, renowned for its nutritional value, harbours bioactive compounds, including lactoferrin (Lf) [1], immunoglobulins, and functional proteins suggesting broader functionalities beyond nutrition. Lf, an iron glycoprotein, exhibits antimicrobial properties against bacteria, fungi, and viruses."In"this st"dy, Immune Powder (a functional dairy formulation) and Fractionated Milk Protein (FMP; a blend of bioactive proteins isolated from skim milk) containing Lf, zinc, and immunoglobulins produced by Ausnutria Australia Dairy Pty Ltd were evaluated for their broad spectrum pharmacological activity. In particular, the study aims to investigate the antibacterial (against pathogenic Escherichia coli), prebiotic (promoting Lactobacillus delbrueckii growth), anti-inflammatory (against RAW264.7 macrophages), and antiviral (against human coronavirus 229E, HCoV-229E cultured on MCR-5 cells) effects of the formulations. In addition, the impact of simulated gastric digestion on the efficacy of the formulations was explored. LCMS-based proteomics analysis was implemented to unveil cellular and molecular mechanisms underlying antiviral activity. The Immune Powder demonstrated antibacterial activity against E. coli (up to 99.74 ± 11.47% inhibition at 62.5 mg/mL), coupled with prebiotic action (10.84 ± 2.2 viability fold change at 125 mg/mL), albeit diminished post-digestion (p <0.01). The Immune Powder effectively mitigated inflammation by reducing NO production, with efficacy declining post-digestion (p < 0.0001). The potential antiviral activity of Immune Powder against HCoV-229E also shown an increase of 2.62 ± 0.42 in cell viability when treated at 500 µg/mL. Similarly, FMP exhibited antibacterial potency pre-digestion at high concentration (95.56 ± 1.23% inhibition at 125 mg/mL), and post-digestion at lower doses (61.82 ± 5.58% inhibition at 3906.25 µg/mL). FMP also shown enhanced prebiotic activity post-digestion (p < 0.0001), anti-inflammation pre-digestion, and significant antiviral activity against HCoV-229E (1.72 ± 0.52 cell viability fold change). The proteomics study suggested both formulas shared similar antiviral mechanism by inhibiting scavenger receptor binding and ECM interaction.
2024-12-02 | PXD052339 | Pride
Project description:We evaluted the synergyistic interactions of cannabidiol (CBD) with standard chemotherapeutic agents such as Docetaxel (DOC), doxorubicin (DOX), paclitaxel (PTX), vinorelbine (VIN), and 7-Ethyl-10-hydroxycamptothecin (SN38) in MCf7 cells ultising different synergy metrics. Then we explored the synergistic mechanisms on the proteome level of the most synergistic combination (CBD and SN38 in a molar ratio of 371:1, respectively)
2021-11-03 | PXD026587 | Pride
Project description:This research explores the antiproliferative effects of short-chain fatty acid (SCFA) salts (magnesium acetate, sodium propionate, and sodium butyrate) on AGS gastric adenocarcinoma cells. Sodium butyrate (NaB) exhibited the most significant inhibitory impact. The study investigated synergistic interactions between NaB and the drug dexamethasone (Dex) using a combination index model. Dex and NaB at a 2:8 ratio showed strong synergy, surpassing mono treatments in inhibitory activity. NaB induced pro-oxidative effects, countered by Dex in combination. Cell population analyses indicated a shift towards apoptosis with Dex, NaB, and their combination. Proteomic analysis revealed downregulation of the oncogene TNS4, suggesting a potential mechanism for antiproliferative effects. These findings suggest NaB as a potential adjuvant therapy with Dex, prompting further exploration of combination therapies and molecular mechanisms, emphasizing the potential application of these postbiotics in gastric cancer treatment.
2024-02-21 | PXD048617 | Pride
Project description:ATAC-seq samples from 2 species and 2 cell types were generated to study cis-regulatory element evolution. Briefly, previously generated urinary stem cell derived iPS-cells (Homo sapiens) of 2 human individuals and fibroblast derived cynomolgus macaque iPSCs (Macaca fascicularis) of 2 individuals (Geuder et al. 2021) were differentiated to neural progenitor cells via dual-SMAD inhibition as three-dimensional aggregation culture (Chambers et al. 2009; Ohnuki et al. 2014). The NPC lines were cultured in NPC proliferation medium and passaged 2 - 4 times until they were dissociated and subjected to ATAC-seq together with the respective iPSC clones. ATAC-seq libraries were generated using the Omni-ATAC protocol (Corces et al. 2017) with minor modifications.
2023-10-25 | E-MTAB-13373 | biostudies-arrayexpress
Project description:The study reports the synthesis of a series of 4-bisarylureathiouracil derivatives (6a-e) for potential use in breast cancer treatment. In vitro cytotoxicity was assessed in MCF-7 and MDA-MB-231 human breast cancer cell lines, revealing significant anti-cancer activity. Compound 6e exhibited the highest cytotoxicity, with IC50 values of 7.94 μM for MCF-7 and 6.67 μM for MDA-MB-231, although it was also the most toxic to RAW 264.7 macrophage cells. In contrast, compound 6c demonstrated strong efficacy against both cancer cell lines (IC50 = 9.23 ± 0.6 μM for MCF-7 and 7.72 ± 0.6 μM for MDA-MB-231) while maintaining selectivity (SI values >10.8 and > 12.9, respectively). Flow cytometry and caspase-3 assays indicated that compounds 6a-c induced apoptosis in MCF-7 cells. In anti-inflammatory assays, compounds 6a and 6d showed significant effects, while 6c demonstrated the weakest, suggesting its cytotoxicity is not linked to anti-inflammatory properties. Compound 6c was prioritised for further investigation because of its preferential targeting of cancer cells. Proteomic analysis of 6c-treated cells revealed significant dysregulation of apoptosis, angiogenesis and VEGF signalling, Rho signal transduction, and pi3k-akt signalling pathways. These findings highlighted the potential of compounds 6a-e as effective anticancer agents, warranting further investigation and optimization for therapeutic applications.
2025-07-19 | PXD065576 | Pride
Project description:The filarial nematodes Brugia malayi, Wuchereria bancrofti and Onchocerca volvulus cause elephantiasis, dermatitis and blindness, resulting in severe morbidity in developing countries. 1.3 billion people are at risk of infection. Targeting the essential Wolbachia endobacteria of filarial nematodes with doxycycline has proven to be an effective therapy, resulting in a block in embryogenesis and worm development, and macrofilaricidal effects. However, doxycycline is contraindicated for a large portion of the at-risk population. To identify new targets for anti-wolbachial therapy, understanding the molecular basis of the Wolbachia-filaria symbiosis is required. We performed cross-species hybridization by using the Brugia malayi microarray to identify differentially expressed genes in the rodent filaria Litomosoides sigmodontis after depletion of Wolbachia which therefore might have a role in symbiosis. Female adult Litomosoides sigmodontis from patent infections were treated with tetracycline to deplete endosymbiotic Wolbachia bacteria. RNA from tetracycline-treated Litomosoides sigmodontis was compared to untreated age-matched control worms. This experiment was performed for three different timepoints: day 6, 15 and 36 of tetracycline treatment. One biological replicate was performed each with two technical replicates (dye-flip replicates).
2010-04-07 | E-GEOD-20976 | biostudies-arrayexpress
Project description:The objective of our study was to search for survival biomarkers (SB) and treatment response monitoring biomarkers (TRMB) in the urinary proteome of dogs with renal disease secondardy to canine leishmaniosis (CanL),
2023-07-20 | PXD042578 | Pride
Project description:Although costly to maintain, protein homeostasis is indispensable for normal cellular function and long-term health. In mammalian cells and tissues, daily variation in global protein synthesis has been observed, but its utility and consequences for proteome integrity are not fully understood. Using several different pulse-labelling strategies, here we gain direct insight into the relationship between protein synthesis and abundance proteome- wide. We show that protein degradation varies in-phase with protein synthesis, facilitating rhythms in turnover rather than abundance. This results in daily consolidation of proteome renewal whilst minimising changes in composition. Coupled rhythms in synthesis and turnover are especially salient to the assembly of macromolecular protein complexes, particularly the ribosome, the most abundant species of complex in the cell. Daily turnover and proteasomal degradation rhythms render cells and mice more sensitive to proteotoxic stress at specific times of day, potentially contributing to daily rhythms in the efficacy of proteasomal inhibitors against cancer. Our findings suggest that circadian rhythms function to minimise the bioenergetic cost of protein homeostasis through temporal consolidation of protein turnover.
2024-05-16 | PXD049176 | Pride
Project description:Found how E. coli responds to the commonly prescribed antibiotic-inhibitor combination piperacillin and tazobactam, separately and in combination. TraDIS-Xpress was performed following the protocol outlined by Yasir et al 2020 Genome Research. The results suggest tazobactam triggers the activity of multidrug efflux systems that have been previously seen to confer clinical resistance to multiple classes of antibiotics.
2023-08-31 | E-MTAB-13226 | biostudies-arrayexpress